|
M. Meckel, R. Bergmann, M. Miederer, F. Rösch.
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates ofbisphosphonic acid, pamidronic acid and zeledronic acid.
EJNMMI Radiopharmacy and Chemistry 2016 1:14
DOI: 10.1186/s41181-016-0017-1
A.T. Reibel, S.S. Müller, S. Pektor, N. Bausbacher, M. Miederer, H. Frey, F. Rösch.
Fate of linear and branched polyether-lipids in vivo in comparison to their liposomal formulations by (18)f-radiolabeling and positron emission tomography.
Biomacromolecules. 2015 Mar 9;16(3):842-51. doi: 10.1021
H. Schieferstein, M. Piel, F. Beyerlein, H. Lüddens, N. Bausbacher, H.-G. Buchholz, T.L. Ross, F. Rösch.
Selective binding to monoamine oxidase A: in vitro and in vivo evaluation of (18)F-labeled β-carboline derivatives.
Bioorg Med Chem. 2015 Feb 1;23(3):612-23. doi: 10.1016
O. Thews, M. Zimny, E. Eppard, M. Piel, N. Bausbacher, V. Nagel, F. Rösch.
In vitro and in vivo structure-property relationship of 68Ga-labeled Schiff base derivatives for functional myocardial pet imaging.
Mol Imaging Biol. 2014 Dec;16(6):802-12. doi: 10.1007/s11307-014-0750-3
M. Piel, U. Schmitt, N. Bausbacher, H.-G. Buchholz, G. Gründer, C. Hiemke, F. Rösch.
Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies
Neuropharmacology Volume 84, September 2014, Pages 152–158
J.F. Cremer, K. Amunts, J. Graw, M. Piel, F. Rösch, K. Zilles.
Neurotransmitter receptor density changes in Pitx3ak mice – a model of Parkinson´s disease
J Neuroscience
J.1Holub, M. Meckel, V. Kubíček, F. Rösch, P. Hermann.
Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging.
Contrast Media Mol Imaging. 2014 May 6.
doi: 10.1002/cmmi.1606. [Epub ahead of print]
M. Meckel, M. Fellner, N. Thieme, R. Bergmann, V. Kubicek, F. Rösch.
In vivo comparison of DOTA based 68Ga-labelled bisphononates for bone imaging in non-tumour models
Nuclear Medicine and Biology (40 (2013) 823-830
I. Vernaleken, M. Klomp, O. Moeller, M. Raptis, A. Nagels, F. Rösch, W.M. Schaefer, P. Cumming, G. Gründer.
Vulnerability to psychiotic effects of ketamine is associated with elevated D2/3 receptor availability
Int J Neuropsychopharm 16 (2013), 16, 745-754
DOI: 10.1017/S14611457120000764
M. Allmeroth, D. Moderegger, D. Gündel, H.-G. Buchholz, N. Mohr, A. Koynov, F. Rösch, O. Thews, R. Zentel.
PEGylation of HPMA-based block copolymers enhances tumor accumulation in vivo: A quantitative study using radiolabeling and positron emission tomography.
Journal of Controlled Release 172 (2013) 77–85
M. Allmeroth, D. Moderegger, D. Gündel, K. Koyonov, H.-G. Buchholz, K. Mohr, F. Rösch, R. Zentel, O. Thews.
HPMA-LMA copolymer drug carriers in oncology: An in vivo PET study to assess the tumor line-specific polymer uptake and body distribution.
Biomacromolecules 14 (2013) 3091-3101.
dx.doi.org/10.1021/bm400709z
S. Eigner, V. Beckford, M. Fellner, N.S. Loktionova, M. Piel, O. Lebeda, F. Rösch, T.L. Ross, K. Eigner-Henke.
Imaging of protein synthesis: In vitro and in vivo evaluation of 44Sc-DOTA-Puromycin
Mol Imaging Biol 15/1 (2013) 79-86
DOI: 10.1007/s11307-012-0561-3
W. Mohnike, B. Zimontkowski, S. Höhnemann, F. Rösch.
Produktion von PET-Radiopharmaka für den klinischen Gebrauch am Beispiel des MVZ-DTZ Berlin
Der Nuklearmediziner 36 (2013) 27–32
I. Vernaleken, M. Klomp, O. Moeller, M. Raptis, A. Nagels, F. Rösch, W. M. Schaefer, P. Cumming, G. Gründer.
Vulnerability to psychiotic effects of ketamine is associated with elevated D2/3 receptor availability
Int J Neuropsychopharm 16 (2012) 1-10.
DOI: 10.1017/S14611457120000764
O. Thews, W. Dillenburg, F. Rösch, M. Fellner.
PET imaging of the impact of extracellular pH and MAP kinases on the p-Glycoprotein (Pgp) activity.
Adv Exp Med Biol. 765 (2013) 279-86.
P. Cumming, G. Xiong, C. LaFougere, A. Rominger, P. Bartenstein, H.-G. Buchholz, M. Piel, F. Rösch, G. Gründer, I. Vernaleken.
Surrogate markers for cerebral blood flow correlate with [18F]-fallypride binding potential at dopamine D2/3 receptors in human striatum.
Synapse 67/4 (2013) 199-203
10.1002/syn.21630.
M. Piel, F. Rösch.
Radiopharmaceutical chemistry.
In: G Gründer (ed.) Molecular imaging in the clinical neurosciences. Humana Press / Springer, Springer, New York, Heidelberg, Dordrecht, London, 2012, Pp. 41-73.
DOI: 10.1007/7657 2012 41.
M.-H. Herth, V. Kramer, N. Gillings, F. Rösch, G.M. Knudsen.
Direct radiofluorination of [18F]MH.MZ for 5-HT2A receptor molecular imaging with PET.
J Label Compd Radiopharm 55 (2012) 354-558.
M. Best, A.N. Gifford, S.W. Kim, B. Babst, M. Piel, F. Rösch, J.S. Fowler.
Rapid radiosynthesis of [11C] and [14C]azelaic, suberic and sebacic acids for in vivo mechanistic studies of systemic acquired resistance in plants.
J. Label. Compd. Radiopharm. 55 (2012) 39-43
P.-J. Riss, J.-M. Hooker, C. Shea, Y. Xu, P. Carter, D. Warner, V. Ferrari, S. W. Kim, F.I. Aigbirhio, J.S. Fowler, F. Rösch.
Characterisation of [¹¹C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter.
Bioorg Med Chem Lett. 22(1) 2012) 679-82.
M. Allmeroth, D. Moderegger, B. Biesalski, K. Koynov, F. Rösch, O. Thews, R. Zentel.
Modifying the body distribution of HPMA-based copolymers by molecular weight and aggregate formation.
Biomacromolecules. 12(7) (2011) 2841-9.
K.N. Spreckelmeyer, M. Paulzen, M. Raptis, T. Baltus, S. Schaffrath, J. Van Waesberghe, MM. Zalewski, F. Rösch, I. Vernaleken, W.M. Schäfer, G. Gründer.
Opiate-induced dopamine release is modulated by severity of alcohol dependence: An [18F]fallypride PET study
Biological Psychiatry (2011) [Epub ahead of print]
I. Vernaleken, L. Peters, M. Raptis, R. Lin, H.-G. Buchholz, Zhou Yun, O. Winz, F. Rösch, P. Bartenstein, D. Wong, W. Schaefer, G. Gründer
The Applicability of SRTM in [18F]Fallypride PET Investigations: Impact of Scan Durations
JCBFM 31 (2011). JCBFM-0565-10-ORIG.R1 [Epub ahead of print]
U. Schmitt, DE. Lee, M.M. Herth, M. Piel, H.-G. Buchholz, F. Rösch, C. Hiemke, H. Lueddens, F. Debus.
P-Glycoprotein Influence on the Brain. Uptake of a 5-HT 2A Ligand: [18F]MH.MZ.
Neuropsychobiology 63 (2011) 183–190. DOI: 10.1159/000321594
V. Kumar, D.K. Boddeti, S.C. Evans, F. Rösch, R. Howman-Giles.
Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection
Nuclear Medicine and Biology 38 (2011) 393–398
M. Fellner, P.J. Riss, NS. Loktionova, KP. Zhernosekov, O. Thews, CFGC. Geraldes, Z. Kovacs, I. Lukes, F. Rösch.
Comparison of different phosphorus-containing ligands complexing 68Ga for PET-imaging of bone metabolism
Radiochimica Acta 99/1 (2011) 43-51.
M. Fellner, W. Dillenburg, H.-G. Buchholz, N. Bausbacher, M. Schreckenberger, F. Renz, F. Rösch, O. Thews.
Assessing p-glycoprotein (Pgp) activity in vivo utilizing 68Ga-Schiff base complexes
Mol Imaging Biol.13(5) (2011) 985-94.
E. Hühn, H.-G. Buchholz, G. Shazly, S. Maus, O. Thews, N. Bausbacher, F. Rösch, M. Schreckenberger, P. Langguth.
Predicting the in vivo release from a liposomal formulation by IVIVC and non-invasive positron emission tomography imaging
Eur J Pharm Sci. 41/1 (2010) 71-77.
O. Thews, W. Dillenburg, M. Fellner, H.-G. Buchholz, N. Bausbacher, M. Schreckenberger, F. Rösch.
Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer
Eur J Nucl Med Mol Imaging. 37(10) (2010) 1935-42
I. Vernaleken, H. Janouschek, M. Raptis, S. Hellmann, T. Veselinovic, A. Bröcheler, C. Boy, P. Cumming, C. Hiemke, F. Rösch, W.M. Schäfer, G. Gründer.
Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas
Int J Neuropsychopharmacol 13/7 (2010) 951-960
G. Nikisch, P. Baumann, B. Kießling, M. Reinert, G. Wiedemann, J. Kehr, AA. Mathé, M. Piel, F. Rösch, H. Weisser, P. Schneider, A. Hertel.
Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first - episode schizophrenia treated with quetiapine
J Psychiatr Res 44/12 (2010) 754-9
M. Fellner, R.P. Baum, J.A. Peters, I. Lukeš, P. Hermann, V. Prasad, F. Rösch
PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosponates - first in human study
Eur J Nucl Med Mol Imaging 37(4) (2010) 834
I. Vernaleken, H. Janouschek, M. Raptis, S. Hellmann, T. Veselinovic, A. Bröcheler, C. Boy, P. Cumming , C. Hiemke, F. Rösch, W.M. Schäfer, G. Gründer
Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas
Int J Neuropsychopharmacol. 13/7 (2010) 951-960
M. Fellner, R.P. Baum, J.A. Peters, I. Lukeš, P. Hermann, V. Prasad, F. Rösch
PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosponates - first in human study
Eur J Nucl Med Mol Imaging 37(4) (2010) 834
M. Herth, F. Debus, M. Piel, M. Palner, G.M. Knudsen, H. Lüddens, F. Rösch
Total synthesis and evaluation of [18F]MHMZ
Bioorg Med Chem Lett., 2008, 18 (4), p. 1515-1519
Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.
Striatal and extrastriatal D2/3-receptor-binding properties of ziprasidone: a positron emission tomography study with
[18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
J Clin Psychopharmacol 28(6) (2008) 608-617.
I.Vernaleken, C. Weibrich, T. Siessmeier, H.-G. Buchholz, F. Rösch, A. Heinze, P. Cummingf, P. Stoeter, P. Bartenstein, G. Gründer
Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age
NeuroImage, 2007, 34(3), p.870-878
G. Gründer, C. Fellows, H. Janouschek, T. Veselinovic, C. Boy, A. Bröcheler, K.M. Kirschbaum, S. Hellmann, K.M. Spreckelmeyer, C. Hiemke, F. Rösch, W.M. Schaefer, I. Vernaleken
The Brain and Plasma Pharmacokinetics of Aripiprazole in Patients with Schizophrenia: a [18F]Fallypride PET Study
American J Psychiatry, Articles, 2008, accepted
C. Fehr, I. Yakushev, N. Hohmann, H.-G. Buchholz, C. Landvogt, H. Deckers, A. Eberhardt, M. Kläger, MN. Smolka,
A. Scheurich, T. Dielentheis, L.G. Schmidt, F. Rösch, P. Bartenstein, G. Gründer, M. Schreckenberger
Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse
Am J Psychiatry 165 (2008) 507-515
M. Jennewein, M.A. Lewis, D. Zhao, E. Tsyganov, N. Slavine, J. He, L. Watkins, P.P. Antich, A. Hermanne, .F Rösch, R.P. Mason, P.E. Thorpe
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine
Clin. Cancer Res, 2008, in press
T. Kienast, T. Siessmeier, J. Wrase, D.F. Braus, MN. Smolka, H.-G. Buchholz, M. Rapp, M. Schreckenberger, F. Rösch, P. Cumming, G. Gruender, K. Mann, P. Bartenstein, A. Heinz
Ratio of dopamine synthesis capacity to D2 receptor availability in ventral striatum correlates with central processing of affective stimuli
Eur J Nucl Med Mol Imaging 35 (2008) 1147-1158
M. Piel, A. Bauman, R.P. Baum, S. Höhnemann, I. Klette, R. Wortmann, F. Rösch
Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imaging
Bioorg. Med. Chem., 2007, 15, p. 3171-3175
D. Stark, M. Piel, H. Hübner, P. Gmeiner, G. Gründer, F. Rösch
In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D2-like dopamine receptors
Bioorg. Med. Chem., 2007, 15, p. 6819-6829
T. Siessmeier, T. Kienast, J. Wrase, JL. Larsen, D.F. Braus, MN. Smolka, H.-G. Buchholz, M. Schreckenberger, M. Rösch, P. Cumming, K. Mann, P. Bartenstein, A. Heinz
Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer
Mov Disord. 21 (2006) 1285-1287
F. Rösch, K.P. Zhernoseko, D.V. Filosofov, M. Jahn, M. Jennewein
The status and the potential of new radionuclide generators providing positron emitters to synthesise new targeting vectors for PET
IAEA-CN-130/068, 2006
E.N. Tsyganov, J. Anderson, G. Arbique, A. Constantinescu, M. Jennewein, P.V. Kulkarni, R.P. Mason, R.W. McColl,
O.K. Öz, R.W. Parkey, E. Richer, F. Rösch, S.Y. Seliounine, N.V. Slavine, S.C. Srivastava, P.E. Thorpe PE, A.I. Zinchenko, P.P Antich
UTSW small animal positron emission imager
IEEE Transactions on Nuclear Science, 2006, 53, p. 2591-2600
A. Bartoli, N. Belcari, D. Stark, S. Höhnemann, M. Piel, M. Jennewein, U Schmitt, J. Tillmanns, O. Thews, C. Hiemke,
F. Rösch, A. Del Guerra.
Preliminary assessment of the imaging capability of the YAP-(S)PET small animal scanner in neuroscience
Nucl Instr Methods A 569, 2006, p. 488-491
G. Gründer, C. Landvogt, I. Vernaleken, H.-G Buchholz, J. Ondracek, T. Siessmeier, S. Härtter, P. Stoeter, O. Rousset, D. F. Wong, C. Hiemke, F. Rösch.
The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia
Neuropsychopharmacology, 2006 31, p. 1027–1035
T. Siessmeier, T. Kienast, J. Wrase, J.L. Larsen, D.F. Braus, M.N. Smolka, H.G. Buchholz, M. Schreckenberger, F. Rösch, P. Cumming, K. Mann, P. Bartenstein, A. Heinz.
Net influx of plasma 6-[18F]fluoro-L-DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli
Eur. J. Neuroscience, 2006, 24(1), p. 305-13
F. Rösch, G. Gründer, M. Schreckenberger, G. Dannhardt
Radiopharmazeutische Entwicklungen für die Molekulare Bildgebung von Prozessen im Zentralen Nervensystem
Healthy Academy 01/2006, pp. 38-53. in: Molecular Imaging. Innovationen und Visionen in der medizinischen Bildgebung. Herausgeber: W. Niederlag, H.U. Lemke, W. Semmler, C. Bremer
K.J. Werhahn, C. Landvogt, S. Klimpe, H.-G. Buchholz, W. Müller-Forell, I. Yakushev, M. Piel, F. Rösch, M. Schreckenberger, P. Bartenstein.
Decreased temporal dopamine D2/D3receptor binding in temporal lobe epilepsy: an 18F-Fallypride PET study
Epilepsia, 2006, 47, p. 1392-1396
U. Baumgärtner, H.-G. Buchholz, A. Bellosevich, W. Magerl, T. Siessmeier, R. Rolke, S. Höhnemann, M. Piel, F. Rösch, H.-J. Wester, G. Henriksen, P. Stoeter, P. Bartenstein, R.-D. Treede, M. Schreckenberger
High opiate receptor binding potential in the human lateral pain system
Neuroimage 30 (2006) 692-699
H. Herzog , F. Rösch
Chemistry and physics of scanners. PET- and SPECT-techniques
Pharm Unserer Zeit 34(6) (2005) 468-73
S. Schneider, E. Schirrmacher, M. Schreckenberger, M. Schwanstecher, C. Schwanstecher, P. Feilen, H. Bucholz,
O. Thews, K. Oberholzer, A. Korobeynikov, A. Bauman, S. Comagic, M. Piel, E. Schirrmacher, C.-Y. Shiue, A.-A. Alavi,
P. Bartenstein, F. Rösch, M.-M. Weber, H.-H. Klein, R. Schirrmacher
In vitro and in vivo evaluation of novel fluorinated glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans
Exp. Clin.Endocrinol Diabetes, 2005, 113(7), p. 388-395
A. Heinz, T. Siessmeier, J. Wrase, H.-G. Buchholz, G. Gründer, Y. Kumakura, P. Cumming, M. Schreckenberger,
MN. Smolka, F. Rösch, K. Mann, P. Bartenstein
Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: A combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients
Am J Psychiatry 8 (2005) 1515-20
A. Helisch, E. Schirrmacher, O. Thews, R. Schirrmacher, H.-G. Buchholz, W. Dillenburg, S. Höhnemann, J. Tillmanns,
I. Wessler, R. Buhl, F. Rösch, P. Bartenstein
Demonstration of pulmonary beta(2)-adrenergic receptor binding in vivo with [18F]fluoroethyl-fenoterol in a guinea pig model
Eur J Nucl Med Mol Imaging 32 (2005) 1324-1328
T. Siessmeier, Yun Zhou, H.-G. Buchholz, C.H. Landvogt, I. Vernaleken, M. Piel, R. Schirrmacher, F. Rösch, M. Schreckenberger, DF. Wong, P. Cumming, G. Gründer, P. Bartenstein
Parametric mapping of the binding in human brain of D2-receptor ligands of different affinities
J Nucl Med 6 (2005) 964-972
K. Zhernosekov, P. Aschoff, D. Filosofov, M. Jahn, M. Jennewein, H.J. Adrian, H. Bihl, F. Rösch
Visualisation of a somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECT
Eur J Nucl Med Mol Imaging 32 (2005) 1129
B. Kaina, U. Mühlhausen, A. Piee-Staffa, M. Christamnn, R. Garcia Boy, F. Rösch, R. Schirrmacher
Inhibition of O6-methylguanine-DNA methyltransferase (MGMT) by glucose-conjugated inhibitors: Comparison with non-conjugated inhibitors and effect on fotemustine and temolozomide-induced cell death
J Pharmacol Exptl Therap 311 (2004) 585-593
A. Heinz, T. Siessmeier, J. Wrase, D. Hermann, S. Klein, SM. Grüsser-Sinopoli, H. Flor, D.F. Braus,
H.-G. Buchholz, G. Gründer, M. Schreckenberger, M. Smolka, F. Rösch, K. Mann, P. Bartenstein
Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving
Am J Psychiatry 161 (2004) 1783-1789
M. Schreckenberger, S. Hägele, T. Siessmeier, H.-G. Buchholz, H. Armbrust-Henrich, F. Rösch, G. Gründer,
P. Bartenstein, T. Vogt.
The dopamine D2-like receptor ligand 18F-Desmethoxyfallypride: An appropriate fluorinated PET tracer for the differential diagnosis of Parkinsonism
Eur. J. Nucl. Med. Mol. Imaging.,2004, 31(8), p.1128-35
I. Vernaleken, T. Siessmeier, H.-G. Buchholz, S. Härtter, C. Hiemke, P. Stoeter, F. Rösch, P Bartenstein, G. Gründer.
High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of schizophrenic patients: implications for atypical antipsychotic mechanism of action.
International J Neuropsychopharmacol, 7/4 (2004), 421-430
M. Schreckenberger, S. Hägele, T. Siessmeier, H.-G. Buchholz, H. Armbrust-Henrich, F. Rösch, P. Bartenstein, T. Vogt.
The dopamine D2-like receptor ligand 18F Desmethoxyfallypride: An appropriate fluorinated PET tracer for the differential diagnosis of Parkinsonism.
Eur. J. Nucl. Med. Mol. Imaging, 8 (2004) 1128–1135.
A. Heinz, T. Siessmeier, J. Wrase, D. Hermann, S. Klein, S.M. Grüsser , H. Flor , D.F. Braus, H.G. Buchholz, G. Gründer,
M. Scheckenberger, M. Smolka, F. Rösch, K. Mann, P. Bartenstein.
Nucleus accumbens dopamin D2 receptors and alcohol craving
J. Neuroscience, 2004
G. Gründer, T. Siessmeier, M. Piel, I. Vernaleken, H.-G. Buchholz, Yun Zhou, C. Hiemke, D. Wong, F. Rösch,
P. Bartenstein.
Quantification of D2-like dopamine receptors in the human brain with [18F]desmethoxyfallypride
J. Nucl. Med., 2003, 44, p. 109-116
H.-G. Buchholz, H. Herzog, G.J. Förster, H. Reber, O. Nickel, F. Rösch, P. Bartenstein.
PET Imaging with Yttrium-86: Comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction
Eur. J. Nucl. Med., 2003, 30, p. 716-720
G. Gründer, T. Siessmeier, C. Lange-Asschenfeldt, I. Vernaleken, H.-G. Buchholz, P. Stoeter, A. Drzezga, H. Lüddens,
F. Rösch, P. Bartenstein.
[18F]fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors
Eur. J. Nucl. Med., 2001, 28, p. 1463-1470
G.J. Förster, M. Engelbach, J. Brockmann, H. Reber, H.-G. Buchholz, H.R Mäcke, F. Rösch, H. Herzog, P. Bartenstein.
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide
Eur. J. Nucl. Med., 2001, 28, p. 1743-1750
F. Rösch, H. Herzog, B. Neumaier, H.W. Müller-Gärtner, G. Stöcklin.
Quantitative whole-body pharmacokinetics of Yttrium-86 complexes with PET and radiation dose calculation of analogous Yttrium-90 radiotherapeuticals
„Sixth International Radiopharmaceutical Dosimetry Symposium“ Gatlinburg, Tennessee (1999) Conference proceedings pp 101-110
F. Rösch, H. Herzog, B. Stolz, J. Brockmann, M. Köhle, H. Mühlensiepen, P. Marbach, H.W. Müller-Gärtner.
Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-Dphe1-Tyr3-octreotide ([86Y]S.M.T 487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
Eur. J. Nucl. Med., 1999, 26, p. 358-366
F. Rösch, H. Herzog, C. Plag, B. Neumaier, U. Braun, H.W. Müller-Gärtner, G. Stöcklin.
Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography
Eur. J. Nucl. Med., 1996, 23, p. 958-966
H. Herzog, F. Rösch , G. Stöcklin, C. Lueders, S.M. Qaim, L.E. Feinendegen.
Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics
J. Nucl.Med., 1993, 34, p. 2222-2226
F. Rösch, G. Gründer, M. Schreckenberger, G. Dannhardt.
Radiopharmaceutical strategies and clinical applications. Diagnosis of CNS disease with PET as well as SPECT
Pharm Unserer Zeit 34(6) (2005) 474-82. Erratum in: Pharm Unserer Zeit 35(1) (2006) 7
A. Heinz, T. Siessmeier, J. Wrase, H.-G. Buchholz, G. Gründer, Y. Kumakura, P. Cumming, M. Schreckenberger,
MN. Smolka, F. Rösch, K. Mann, P. Bartenstein.
Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: A combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients
Am J Psychiatry 8 (2005) 1515-20
A. Helisch, E. Schirrmacher, O. Thews, R. Schirrmacher, H.-G. Buchholz, W. Dillenburg, S. Höhnemann, J. Tillmanns,
I. Wessler, R. Buhl, F. Rösch, P. Bartenstein.
Demonstration of pulmonary beta(2)-adrenergic receptor binding in vivo with [18F]fluoroethyl-fenoterol in a guinea pig model
Eur J Nucl Med Mol Imaging 32 (2005) 1324-1328
U. Mühlhausen, R. Schirrmacher, M. Piel, B. Lecher, G. Nagel, A. Pie-Staffa, B. Kaina, F. Rösch.
Synthesis of I-131 labeled glucose-conjugated inhibitors of O6-Methylguanine-DNA Methyltransferase (MGMT) and comparison with non-conjugated Inhibitors as potential tools for in vivo MGMT imaging
J Med Chem, 12 (2005) 263-72
S. Schneider, P.J. Feilen, M. Schreckenberger, M. Schwanstecher, C. Schwanstecher, H.-G. Buchholz, O. Thews,
K. Oberholzer, A. Korobeynikov, A. Bauman, S. Comagic, M. Piel, E. Schirrmacher, CY. Shiue, AA. Alavi, P. Bartenstein,
F. Rösch, M.M. Weber, H.H. Klein, R. Schirrmacher.
In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans
Exp Clin Endocrinol Diabetes 7 (2005) 388-395
T. Siessmeier, Yun Zhou, H.-G. Buchholz, Ch. Landvogt, I. Vernaleken, M. Piel, R. Schirrmacher, F. Rösch,
M. Schreckenberger, DF. Wong, P. Cumming, G. Gründer, P. Bartenstein.
Parametric mapping of the binding in human brain of D2-receptor ligands of different affinities
J Nucl Med 6 (2005) 964-97
K. Zhernosekov, A. Aschoff, D. Filosofov, M. Jahn, M. Jennewein, H.J. Adrian, H. Bihl, F. Rösch.
Visualisation of a somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECT
Eur J Nucl Med Mol Imaging 32 (2005) 1129
F. Rösch
Radionuklid-Generatorsysteme für die PET
Der Nuklearmediziner 27 (2004) 226-235
B. Wängler, C. Beck, CY. Shiue, S. Schneider, C. Schwanstecher, M. Schwanstecher, P.J. Feilen, A. Alavi, F. Rösch,
R. Schirrmacher.
Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent
Bioorg Med Chem Lett 14/20 (2004) 5205-5209
M. Schreckenberger, S. Hägele, T. Siessmeier, H.-G. Buchholz, H. Armbrust-Henrich, F. Rösch, G. Gründer,
P. Bartenstein, T. Vogt.
The dopamine D2-like receptor ligand 18F-Desmethoxyfallypride: An appropriate fluorinated PET tracer for the differential diagnosis of Parkinsonism
Eur J Nucl Med Mol Imaging 8 (2004) 1128-1135
A. Schmitz, C-Y Shiue, Q. Feng, GG. Shiue, S. Deng, MT. Pourdehnad, R. Schirrmacher, M. Vatamaniuk, N. Doliba,
F. Matschinsky, B. Wolf, F. Rösch, A. Naji, AA. Alavi.
Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents
Nucl Med Biol 31 (2004) 483-491
B. Wängler, S. Schneider, O. Thews, E. Schirrmacher, S. Comagic, P. Feilen, C. Schwanstecher, M. Schwanstecher,
C-Y. Shiue, A. Alavi, S. Höhnemann, M. Piel, F. Rösch, R. Schirrmacher.
Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET)
Nucl Med Biol 31 (2004) 639-647
R. Schirrmacher, S. Comagic, E. Schirrmacher, F. Rösch.
Synthesis of a technetium-99m labeled L-tyrosine derivative with the fac-99mTc(I)(CO)3-core for imaging cancer
J Label Compd Radiopharm 47 (2004) 477-483
A. Bauman, M. Piel, R. Schirrmacher, F. Rösch.
Efficient alkali iodide promoted 18F-fluoroethylations with 2-[18F]fluoroethyl tosylate and 1-bromo-2-[18F]fluoroethane
Tetrahedron Letters 44 (2003) 9165-9167
M. Piel, R. Schirrmacher, S. Höhnemann, W. Hamkens, B. Kohl, M. Jansen, U. Schmitt, H. Lüddens, G. Dannhardt,
F. Rösch.
Synthesis and evaluation of 5,7-dichloro-4-(3-{4-[4-(2-[18F]fluoroethyl)-piperazin-1-yl]-phenyl}-ureido)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid as a potential NMDA ligand to study glutamergic neurotransmission in vivo
J Label Compd Radiopharm 46 (2003) 645-659
H.-G. Buchholz, H. Herzog, G.-J. Förster, H. Reber, O. Nickel, F. Rösch, P. Bartenstein.
PET Imaging with Yttrium-86: Comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction.
Eur J Nucl Med 30 (2003) 716-720
E. Schirrmacher, R. Schirrmacher, A. Helisch, W. Dillenburg, O. Thews, I. Wessler, R. Buhl, S. Höhnemann,
H.-G. Buchholz, P. Bartenstein, H.J. Machulla, F. Rösch.
Synthesis and preliminary evaluation of (R,R) (S,S) -(2-(2-[4-(2-[F-18]fluoroethoxy)phenyl]-1-methylamino)-1-hydroxyethyl)benzene-1,3-diol ([F-18]FEFE) for the in vivo visualisation and quantification of the ß2-adrenergic receptor status
in lung
Biomed Chem Lett 13/16 (2003) 2687-2692
G. Gründer, T. Siessmeier, M. Piel, I. Vernaleken, H.-G. Buchholz, Yun Zhou, Ch. Hiemke, D. Wong, F. Rösch,
P. Bartenstein.
Quantification of D2-like dopamine receptors in the human brain with [18F]desmethoxyfallypride
J Nucl Med 44 (2003) 109-116
R. Schirrmacher, B. Mathiasch, E. Schirrmacher, D. Radnic, F. Rösch.
Syntheses of novel N-([18F]fluoroalkyl)-N-nitroso-4-methyl-benzensulfonamides and decomposition studies of corresponding 19F- and bromo-analogues: Potential new compounds for the 18F-labelling of radiopharmaceuticals
J Label Compd Radiopharm 46 (2003) 959-977
R. Schirrmacher, E. Nesseler, W. Hamkens, U. Eichhorn, M. Schreckenberger, B. Kaina, F. Rösch.
An approach to the evaluation of the activity of the DNA repair enzyme O6-methylguanine-DNA-methyl-transferase in tumor tissue in vivo: synthesis of 6-benzyloxy-9-(2-[18F]fluoroethyl)-9H-purin-yl-2-amine and 6-benzyloxy-7-(2-[18F]fluoroethyl)-9H-purin-yl-2-amine
Appl Radiat Isot 56 (2002) 511-517
R. Schirrmacher, B. Wängler, E. Schirrmacher, T. August, F. Rösch.
Dimethylpyridin-4-ylamine-catalysed alcoholysis of 2-amino-N,N,N-trimethyl-9H-ylammonium chloride: An effective route to O6-substituted guanine derivatives from alcohols with poor nucleophilicity
Synthesis 4 (2002) 538-542
S. Comagic, M. Piel, R. Schirrmacher, S. Höhnemann, F. Rösch.
Efficient synthesis of 2-bromo-1-[18F]fluoroethane and its application in the automated preparation of 18F-fluoroethylated radiopharmaceuticals
Appl Radiat Isot 56 (2002) 847-851
R. Schirrmacher, M. Weber, A. Schmitz, C.-Y Shiue, AA. Alavi, P. Feilen, S. Schneider, P. Kann, F. Rösch.
Radiosynthesis of 1-(4-(2-[18F]fluoroethoxy)benzenesulfonyl)-butyl urea: A potential ß-cell imaging agent
J Label Compd Radiopharm 45 (2002) 763-774
R. Schirrmacher, U. Mühlhausen, B. Wängler, E. Schirrmacher, .J Reinhard, G. Nagel, B. Kaina, M. Piel, M. Wießler,
F. Rösch.
Synthesis of 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-b-D-glycosyl)-purine: A novel radioligand for positron emission tomography studies of the O6-methylguanine-DNA methyltransferase (MGMT) status of tumour tissue
Tetrahedron Letters 43 (2002) 6301-6304
R. Schirrmacher, W. Hamkens, M. Piel, U. Schmitt, H. Lüddens, Ch. Hiemke, F. Rösch.
Radiosynthesis and evaluation of (2-((4-(2-[18F]fluoroethoxy)phenyl)bis(4-methoxyphenyl)methoxy)-ethylpiperidine-3-carboxylic acid as a potential GAT-3 ligand to study GABAergig neurotransmission in vivo
J Label Compd Radiopharm 44 (2001) 627-642
R. Schirrmacher, G. Shiue, SJ. Shiue, A. Alavi, PJ. Feilen, S. Schneider, J. Beyer, F. Rösch.
Synthesis and first evaluation of new 18F-labelled sulfonylureas for the determination of the beta-cell status in vivo
J Label Compd Radiopharm 44 (2001) S418-420
E. Schirrmacher, R. Schirrmacher, R. Buhl, I. Wessler, H.-J. Machulla, F. Rösch.
Synthesis of [18F]fluoroethylfenoterol for imaging 2 receptor status in lung in vivo
J Label Compd Radiopharm 44 (2001) S436-438
B. Wolf, R. Schirrmacher, G.J. Förster, P. Bartenstein, F. Rösch.
Synthesis and first in vivo-tests of C1-[18F]Ffluoroethylamino asparagine for imaging cancer
J Label Compd Radiopharm 44 (2001) S365-367
S. Comagic, M. Piel, R. Schirrmacher, S. Höhnemann, F. Rösch.
Efficient synthesis of 2-bromo-1-[18F]fluoroethane and its application in the automated preparation of 18F-fluoroethylated radiopharmaceuticals
J Label Compd Radiopharm 44 (2001) S874-876
A. Schildan, R. Schirrmacher, M. Samochocki, C. Christner, A. Maelicke, F. Rösch.
Synthesis and in vitro evaluation of galanthamine derivatives for examination of nicotinic acetylcholine receptor system.
J Label Compd Radiopharm 44 (2001) S247-249
G. Gründer, T. Siessmeier, C. Lange-Asschenfeldt, I. Vernaleken, H.-G. Buchholz, P. Stoeter, A. Drzezga, H. Lüddens,
F. Rösch, P. Bartenstein.
[18F]fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors
Eur J Nucl Med 28 (2001) 1463-1470
G.J. Förster, M. Engelbach, J. Brockmann, H. Reber, H.-G. Buchholz, H.R. Mäcke, F. Rösch, H. Herzog, P. Bartenstein.
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide
Eur J Nucl Med 28 (2001) 1743-1750
F. Rösch, H.-J. Wester, T.R. Degrado.
Current developments of 18F-labeled PET-tracers in oncology
In: HJ Wieler, RE Coleman (eds.), PET in Clinical Oncology, Steinkopff, Darmstadt, 2000, 55-66
H. Hamkens, F. Rösch.
FDG: Biochemical concept and radiochemical synthesis
In: HJ Wieler, RE Coleman (eds.), PET in Clinical Oncology, Steinkopff, Darmstadt, 2000, 55-66
W. Hamkens, M. Piel, R. Schirrmacher, U. Schmitt, R. Kleinz, H. Lüddens, G. Gründer, F. Rösch.
Improved synthesis of 5-(2’-[18F]fluoroethyl)flumazenil for in vivo imaging of benzodiazepine receptors
J Label Compd Radiopharm 42, suppl. 1 (1999) 510-512
F. Rösch, H. Herzog, B. Neumaier, H.W. Müller-Gärtner, G. Stöcklin.
Quantitative whole-body pharmacokinetics of Yttrium-86 complexes with PET and radiation dose calculation of analogous Yttrium-90 radiotherapeuticals
Conference proceedings „Sixth International Radiopharmaceutical Dosimetry Symposium“ Gatlinburg,
Tennessee (1999) pp 101-110
F. Rösch, H. Herzog, B. Stolz, J. Brockmann, M. Köhle, H. Mühlensiepen, P. Marbach, H.W. Müller-Gärtner.
Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-Dphe1-Tyr3-octreotide ([86Y]SMT 487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
Eur J Nucl Med 26 (1999) 358-366
E. Nesseler, R. Schirrmacher, W. Hamkens, F. Rösch.
Synthesis of 2-amino-6-benzyloxy-9-[18F]fluoroethyl-purine, a possible candidate to determine the status of O6-methyl-guanine-DNA-methyltransferase (MGMT) of tumor tissue
J Label Compd Radiopharm 42, suppl. 1 (1999) 198-200
R. Schirrmacher, W. Hamkens, M. Piel, J. Brockmann, F. Rösch
Synthesis of 18F- and 11C-labeled substituted triarylnipecotic acid derivatives with high affinity for the GABA transporter GAT-3
J Label Compd Radiopharm 42, suppl. 1 (1999) 339-341
M. Piel, R. Schirrmacher, W. Hamkens, U. Schmitt, C. Hiemke, G. Gründer, F. Rösch.
Improved precursor synthesis and 18F-fluorination of [18F]desmethoxyfallypride
J Label Compd Radiopharm 42, suppl. 1 (1999) 381-383
F. Rösch
Aktuelle Entwicklungen 18F-markierter onkologischer PET-Tracer
In: HJ Wieler (ed.), PET in der klinischen Onkologie, Steinkopff Verlag,
Darmstadt, 1999, 71-84
G.L. Griffiths, D.M. Goldenberg, F. Rösch, H.J. Hansen.
Radiolabelling of an anti-carcinoembryonic antigen antibody Fab´ fragment (CEA-Scan) with the positron-emitting radionuclide
Tc-94m
Clin Cancer Res 5 (1999) 3001-3003
A.T. Klein, F. Rösch, SM. Qaim.
Production of the positron emitter 51Mn for in vivo evaluation of 51Mn-labeled MRI contrast agents via PET
J Label Compd Radiopharm 39 (1997) 501-503
H.J. Wester, J. Brockmann, F. Rösch, B. Stolz, W. Wutz, H. Herzog, P.M. Smith-Jones, C. Bruns, G. Stöcklin.
Quantitative in vivo uptake kinetics of 18F-octreotide measured by PET: A comparison with 86Y-DTPA-octreotide and 68Ga-DFO-octreotide in tumor bearing rats
Nucl Med Biol 24 (1997) 275-286
F. Rösch, H. Herzog, C. Plag, B. Neumaier, U. Braun, H.W. Müller-Gärtner, G. Stöcklin.
Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography
Eur J Nucl Med 23 (1996) 958-966
B. Neumaier, F. Rösch.
Binding of radioyttrium to human serum albumin: Relevance to endotherapeutic applications of 90Y-labelled pharmaceutics
J Label Compd Radiopharm 37 (1995) 569-570
J. Brockmann, F. Rösch.
Labelling of small peptides with yttrium and gallium via a new DOTA-derivative or DFO using different disuccinimidylic esters as linker
J Label Compd Radiopharm 37 (1995) 516-518
J. Brockmann, F. Rösch, H. Herzog, B. Stolz, C. Bruns, G. Stöcklin.
In vivo uptake kinetics and dosimetric calculations of 86Y-DTPA-octreotide with PET as a model for potential endotherapeutic octreotides labeled with 90Y
J Label Compd Radiopharm 37 (1995) 519-521
G. Stöcklin, SM. Qaim, F. Rösch.
The impact of radioactivity on life sciences
Radiochim Acta 70/71 (1995) 249-272
E.M. Link, A.S. Michalowski, F. Rösch.
211At-Methylene blue in targeted radiotherapy of disseminated melanoma
Pigment Cell Res 7 (1994) 358-362
F. Rösch, AF. Novgorodov, SM. Qaim.
Thermochromatographic separation of 94mTc from enriched molybdenum targets and its large scale production for nuclear medical application
Radiochim Acta 64 (1994) 113-120
F. Rösch, AF. Novgorodov, SM. Qaim, G. Stöcklin.
High purity production of the positron emitting technetium iotope 94mTc
J Label Compd Radiopharm 35 (1994) 267-269
F. Rösch, B. Neumaier, G. Stöcklin, SM. Qaim, H. Herzog, H.W. Müller-Gärtner.
[86Y]Citrate and [86Y]EDTMP: Preparation, chemical characterization and in vivo quantitation of their pharmacological data with PET
J Label Compd Radiopharm 35 (1994) 546-548
F. Rösch, SM. Qaim, G. Stöcklin.
New nuclear data relevant to the production of the positron emitting radioisotope 86Y
J Label Compd Radiopharm 32 (1993) 449-451
F. Rösch, SM. Qaim, G. Stöcklin.
Production of the positron emitting radionuclide 86Y for nuclear medical application
Int J Appl Radiat Isot 44 /4/ (1993) 677-681
F. Rösch, SM. Qaim, G. Stöcklin
Nuclear data relevant to the production of the positron emitting radioisotope 86Y via the 86Sr(p,n)- and natRb(3He,xn)-processes
Radiochim Acta 61 /1/ (1993) 1-8
F. Rösch, SM. Qaim.
Nuclear Data Relevant to the Production of the Positron Emitting Technetium Isotope 94mTc via the 94Mo(p,n)-reaction
Radiochim Acta 62 (1993) 115-121
H. Herzog, F. Rösch, G. Stöcklin, C. Lueders, SM. Qaim, LE. Feinendegen.
Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics
J Nucl Med 34 (1993) 2222-2226
G.J. Beyer, R. Bergmann, G. Kampf, P. Mäding, F. Rösch.
Simultaneous study of the biodistribution of radio-yttrium complexed with EDTMP and citrate ligands in tumour-bearing rats
Nucl Med Biol 19 / 2/ (1992) 201-203
F. Rösch, VA. Khalkin.
Ion mobilities of trivalent f-elements in aqueous electrolytes
Radiochim Acta 51 /3/ (1990) 101-106
|
